MENLO PARK, Calif., March 18, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated dermatology products to dermatologists and their patients, today announced that it will report fourth quarter and full year 2014 financial results after the close of U.S. financial markets on March 25, 2015. Dermira management will host a webcast and conference call at 4:30 p.m. ET/1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.dermira.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 6581763.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira's portfolio of five product candidates targets significant market opportunities and includes three late‐stage product candidates, CIMZIA® (certolizumab pegol), in Phase 3 development in collaboration with UCB Pharma S.A. for the treatment of moderate-to-severe plaque psoriasis; DRM04, a topical treatment for hyperhidrosis; and, DRM01, a topical sebum inhibitor for the treatment of acne. Dermira is headquartered in Menlo Park, California. For more information, please visit www.dermira.com.
CONTACT: Dermira Contact Andrew Guggenhime Chief Operating Officer and Chief Financial Officer 650.421.7200 Investor Contact Westwicke Partners Robert H. Uhl Managing Director 858.356.5932 firstname.lastname@example.orgSource:Dermira